Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 229

Similar articles for PubMed (Select 15713947)

1.

COX-2 inhibitors--a lesson in unexpected problems.

Drazen JM.

N Engl J Med. 2005 Mar 17;352(11):1131-2. Epub 2005 Feb 15. No abstract available.

PMID:
15713947
2.

COX-2 inhibitors--lessons in drug safety.

Psaty BM, Furberg CD.

N Engl J Med. 2005 Mar 17;352(11):1133-5. Epub 2005 Feb 15. No abstract available.

PMID:
15713946
3.

Coxibs and cardiovascular disease.

Fitzgerald GA.

N Engl J Med. 2004 Oct 21;351(17):1709-11. Epub 2004 Oct 6. No abstract available.

4.

Raising the safety bar--the FDA's coxib meeting.

Okie S.

N Engl J Med. 2005 Mar 31;352(13):1283-5. No abstract available.

PMID:
15800221
5.

Drug safety. FDA panel urges caution on many anti-inflammatory drugs.

Couzin J.

Science. 2005 Feb 25;307(5713):1183-5. No abstract available.

PMID:
15731414
6.

COX-2 inhibitors: cancer prevention or cardiovascular risk?

Senior K.

Lancet Oncol. 2005 Feb;6(2):68. No abstract available.

PMID:
15704289
7.

The coxibs, selective inhibitors of cyclooxygenase-2.

FitzGerald GA, Patrono C.

N Engl J Med. 2001 Aug 9;345(6):433-42. Review. No abstract available.

PMID:
11496855
8.

COX-2 inhibitors and cardiovascular toxicity: a class effect?

Laible B.

S D J Med. 2005 Mar;58(3):93-4. No abstract available.

PMID:
15794479
9.

The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).

Wynn RL.

Gen Dent. 2000 Jan-Feb;48(1):16-20. No abstract available.

PMID:
11199547
10.

The COX-2 inhibitors--an update.

Furberg CD.

Am Heart J. 2006 Aug;152(2):197-9. No abstract available.

PMID:
16875896
11.

COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.

Ray WA, MacDonald TM, Solomon DH, Graham DJ, Avorn J.

Pharmacoepidemiol Drug Saf. 2003 Jan-Feb;12(1):67-70. Review. No abstract available.

PMID:
12616850
12.

COX-2 inhibitors. Magic bullets or merely mortal?

[No authors listed]

Harv Health Lett. 2000 Feb;25(4):4. No abstract available.

PMID:
10637015
13.

Differences between COX-2-specific inhibitors: clinical and economic implications.

Sonnenblick EH.

Am J Manag Care. 2002 Oct;8(15 Suppl):S428-30. Review. No abstract available.

14.

COX-2 inhibitors: no pain, no heart gain?

[No authors listed]

Harv Heart Lett. 2001 Dec;12(4):2-4. Review. No abstract available.

PMID:
11751079
15.

[Gastric protective pain therapy. What is the advantage of new COX-2 inhibitors?].

Hinz B, Brune K.

MMW Fortschr Med. 2000 Mar 16;142(11):39-40. German. No abstract available.

PMID:
10786088
16.

[New anti-inflammatory analgetics--are they needed?].

Paakkari I.

Duodecim. 1999;115(20):2217-24. Review. Finnish. No abstract available.

PMID:
11973925
17.

COX-2 inhibitors still eyed for cancer prevention.

Thompson CA.

Am J Health Syst Pharm. 2005 May 1;62(9):890, 894. No abstract available.

PMID:
15851492
18.

COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.

Atkinson HG.

Health News. 2002 Aug;8(8):5. No abstract available.

PMID:
12206146
19.

COX-2 inhibitors: new drugs for the management of pain and inflammation.

Hutchins V, Hutchins B.

Dent Today. 2001 Feb;20(2):56-61. No abstract available.

PMID:
12524847
20.

Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.

Jugdutt BI.

Circulation. 2007 Jan 23;115(3):288-91. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk